Antigen concentration and precursor frequency determine the rate of CD8+ T cell tolerance to peripherally expressed antigens - PubMed (original) (raw)
. 1999 Jul 15;163(2):723-7.
Affiliations
- PMID: 10395663
Antigen concentration and precursor frequency determine the rate of CD8+ T cell tolerance to peripherally expressed antigens
D J Morgan et al. J Immunol. 1999.
Abstract
Expression of transgene-encoded proteins in the pancreatic islets can cause peripheral deletion of T cells. However, tolerance has not been observed in all transgenic models. It has been proposed that the determining factor for successful peripheral tolerance is the amount of Ag cross-presented by quiescent APCs. Using InsHA mice, which demonstrate peripheral tolerance to the influenza virus hemagglutinin (HA) expressed in the pancreatic islet beta cells, we have investigated the consequences when different amounts of HA are expressed. As compared with InsHA mice that are heterozygous for the InsHA transgene, homozygous InsHA mice demonstrated enhanced activation and proliferation of Kd-restricted HA-specific CD8+ T cells in the pancreatic lymph nodes. However, despite such activation, insulitis was not observed, and the T cells were gradually functionally deleted. Deletion of these activated cells occurred much more rapidly in homozygous than in heterozygous InsHA mice. These data demonstrate that there is a direct correlation between the amount of HA expressed in the periphery, and both the degree of T cell proliferation in the pancreatic lymph nodes and the rate of tolerance of HA-specific CD8+ T cells. This strongly supports the hypothesis that activation of T cells through cross-presentation of peripheral Ags in a noninflammatory environment is an important part of the normal mechanism of tolerance to Ags expressed in the pancreatic islets.
Similar articles
- Abortive activation precedes functional deletion of CD8+ T cells following encounter with self-antigens expressed by resting B cells in vivo.
Fraser JM, Janicki CN, Raveney BJ, Morgan DJ. Fraser JM, et al. Immunology. 2006 Sep;119(1):126-33. doi: 10.1111/j.1365-2567.2006.02414.x. Epub 2006 Jun 23. Immunology. 2006. PMID: 16796693 Free PMC article. - CD8(+) T cells specific for beta cells encounter their cognate antigens in the islets of NOD mice.
Pang S, Zhang L, Wang H, Yi Z, Li L, Gao L, Zhao J, Tisch R, Katz JD, Wang B. Pang S, et al. Eur J Immunol. 2009 Oct;39(10):2716-24. doi: 10.1002/eji.200939408. Eur J Immunol. 2009. PMID: 19658094 - Defective CD8+ T cell peripheral tolerance in nonobese diabetic mice.
Kreuwel HT, Biggs JA, Pilip IM, Pamer EG, Lo D, Sherman LA. Kreuwel HT, et al. J Immunol. 2001 Jul 15;167(2):1112-7. doi: 10.4049/jimmunol.167.2.1112. J Immunol. 2001. PMID: 11441123 - Cross-presentation of self antigens to CD8+ T cells: the balance between tolerance and autoimmunity.
Kurts C, Heath WR, Carbone FR, Kosaka H, Miller JF. Kurts C, et al. Novartis Found Symp. 1998;215:172-81; discussion 181-90. doi: 10.1002/9780470515525.ch13. Novartis Found Symp. 1998. PMID: 9760579 Review. - Induction of peripheral CD8+ T-cell tolerance by cross-presentation of self antigens.
Miller JF, Kurts C, Allison J, Kosaka H, Carbone F, Heath WR. Miller JF, et al. Immunol Rev. 1998 Oct;165:267-77. doi: 10.1111/j.1600-065x.1998.tb01244.x. Immunol Rev. 1998. PMID: 9850866 Review.
Cited by
- An mRNA-based broad-spectrum vaccine candidate confers cross-protection against heterosubtypic influenza A viruses.
Xiong F, Zhang C, Shang B, Zheng M, Wang Q, Ding Y, Luo J, Li X. Xiong F, et al. Emerg Microbes Infect. 2023 Dec;12(2):2256422. doi: 10.1080/22221751.2023.2256422. Epub 2023 Sep 6. Emerg Microbes Infect. 2023. PMID: 37671994 Free PMC article. - Robust antigen-specific CD8 T cell tolerance to a model prostate cancer neoantigen.
Lopez-Bujanda ZA, Chaimowitz MG, Armstrong TD, Foote JB, Emens LA, Drake CG. Lopez-Bujanda ZA, et al. Oncoimmunology. 2020 Sep 6;9(1):1809926. doi: 10.1080/2162402X.2020.1809926. Oncoimmunology. 2020. PMID: 33457094 Free PMC article. - Revisiting T Cell Tolerance as a Checkpoint Target for Cancer Immunotherapy.
Nüssing S, Trapani JA, Parish IA. Nüssing S, et al. Front Immunol. 2020 Sep 23;11:589641. doi: 10.3389/fimmu.2020.589641. eCollection 2020. Front Immunol. 2020. PMID: 33072137 Free PMC article. Review. - FOXO3 is differentially required for CD8+ T-cell death during tolerance versus immunity.
Wagle MV, Parish IA. Wagle MV, et al. Immunol Cell Biol. 2016 Oct;94(9):895-899. doi: 10.1038/icb.2016.53. Epub 2016 Jun 21. Immunol Cell Biol. 2016. PMID: 27323690 - Targeting cancer-specific mutations by T cell receptor gene therapy.
Blankenstein T, Leisegang M, Uckert W, Schreiber H. Blankenstein T, et al. Curr Opin Immunol. 2015 Apr;33:112-9. doi: 10.1016/j.coi.2015.02.005. Epub 2015 Feb 27. Curr Opin Immunol. 2015. PMID: 25728991 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous